Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases

International Journal of Clinical Oncology

Volumn 16, Issue 5, 2011, Pages 605-609

  Takano, Masashi ^a   Kikuchi, Yoshihiro ^b   Kudoh, Kazuya ^c   Goto, Tomoko ^a   Furuya, Kenichi ^a   Kikuchi, Ryoko ^a   Kita, Tsunekazu ^d   Fujiwara, Keiichi ^e   Shiozawa, Tanri ^f   Aoki, Daisuke ^g  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

^c National Hospital Organization Nishisaitama Chuo National Hospital   (Japan)

^d NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MTOR inhibitor; Ovarian clear cell carcinoma; Recurrence; Refractory; Temsirolimus

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MITOMYCIN C; NEDAPLATIN; PACLITAXEL; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; RAPAMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TUMOR VOLUME; ADENOCARCINOMA; BLOOD; CASE REPORT; DRUG ADMINISTRATION; MIDDLE AGED; OVARY TUMOR; PATHOLOGY;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SIROLIMUS;

EID: 84857081287     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0177-z     Document Type: Article

References (25)

1. Goff BA, Sainz de la Cuesta R, Muntz HG et al (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60:412-417 (Pubitemid 26077628)
2. Recio FO, Piver MS, Hempling RE et al (1996) Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78:2157-2163 (Pubitemid 26367609)
3. Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88:2584-2589
4. Pectasides D, Fountzilas G, Aravantinos G et al (2006) Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102:285-291 (Pubitemid 44041640)
5. Enomoto T, Kuragaki C, Yamasaki M et al (2003) Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22:abstr 1797
6. Ho CM, Huang YJ, Chen TC et al (2004) Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94:197-203
7. Takano M, Sugiyama T, Yaegashi N et al (2008) Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18:937-942
8. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
9. Bellmunt J, Szczylik C, Feingold J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387-1392
10. Malizzia LJ, Hsu A (2008) Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 12:639-646
11. Lee S, Garner EI, Welch WR et al (2007) Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 106:311-317 (Pubitemid 47087928)
12. Miyazawa M, Yasuda M, Fujita M et al (2009) Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59:19-27
13. Mabuchi S, Kawase C, Altomare DA et al (2009) mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15:5404-5413
14. Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21(10 Suppl):187s-193s
15. Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369-1374 (Pubitemid 43772268)
16. Kuo KT, Guan B, Feng Y et al (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69:4036-4042
17. Osada R, Horiuchi A, Kikuchi N et al (2007) Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38:1310-1320 (Pubitemid 47247486)
18. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253-262
19. Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014
20. Harding MW (2003) Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 9:2882-2886 (Pubitemid 36993244)
21. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554 (Pubitemid 43927103)
22. Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347 (Pubitemid 41115390)
23. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918 (Pubitemid 41103603)
24. Crotzer DR, Sun CC, Coleman RL et al (2007) Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105:404-408 (Pubitemid 46590333)
25. Utsunomiya H, Akahira J, Tanno S et al (2006) Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16:52-56